TY - JOUR
T1 - Establishment of a murine, lipopolysaccharide-induced sepsis model for testing anaerobic exercise thresholds and early mobilization
AU - Matsuishi, Yujiro
AU - Shimojo, Nobutake
AU - Hoshino, Haruhiko
AU - Enomoto, Yuki
AU - Mathis, Bryan J.
AU - Oh, Sechang
AU - Kawano, Satoru
AU - Myoenzono, Kanae
AU - Maeda, Seiji
AU - Shoda, Junichi
AU - Inoue, Shigeaki
AU - Inoue, Yoshiaki
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2021/3
Y1 - 2021/3
N2 - Background: Several methods have been proposed to prevent post intensive care syndrome after sepsis, including early mobilization, but controversy remains in mechanisms and outcomes. Therefore, the aim of this study is to establish a septic mouse model and classify exercise intensities during the acute phase of sepsis to generate a murine sepsis rehabilitation model. Methods: Adult, male C57/B6 mice received lipopolysaccharide (LPS) injections (20 mg/kg). We recorded survival rates and metabolic changes, such as resting energy expenditure (REE), compared with controls up to 72 h after LPS administration. We also observed vital signs (rectal temperature and weight change), inflammation (TNF-α and IL-6), and exercise intensity via metabolic monitoring treadmill. We analyzed the anaerobic threshold (AT) by the V-Slope method. Result: Around 30% of the mice survived 72 h after LPS induction with the lowest REE at around 22–24 h later (REE at 22 h: 2.26 ± 0.34 kcal/day p < 0.05 vs. baseline). Blood concentrations of TNF-α were highest at the 12 h timepoint (41.23 ± 24.39 pg/mL, p < 0.05 vs. baseline) and IL-6 was highest at 24 h after LPS induction (1476.5 ± 274.7 pg/mL, p < 0.05 vs. baseline). With V-Slope, we observed the AT at each timepoint (6 h:14 m/min,12 h: 9 m/min, 24 h:4 m/min,36 h:10 m/min, 48 h:16 m/min, 60 h:20 m/min, 72 h:22 m/min) and classified these into very low intensity exercise training, low intensity exercise training, or moderate intensity exercise training at each timepoint. Conclusion: We classified exercise intensities out to 72 h after sepsis recovery using a mouse model. These data may serve as a bridge to clinical studies to fill gaps in best practice for sepsis rehabilitation.
AB - Background: Several methods have been proposed to prevent post intensive care syndrome after sepsis, including early mobilization, but controversy remains in mechanisms and outcomes. Therefore, the aim of this study is to establish a septic mouse model and classify exercise intensities during the acute phase of sepsis to generate a murine sepsis rehabilitation model. Methods: Adult, male C57/B6 mice received lipopolysaccharide (LPS) injections (20 mg/kg). We recorded survival rates and metabolic changes, such as resting energy expenditure (REE), compared with controls up to 72 h after LPS administration. We also observed vital signs (rectal temperature and weight change), inflammation (TNF-α and IL-6), and exercise intensity via metabolic monitoring treadmill. We analyzed the anaerobic threshold (AT) by the V-Slope method. Result: Around 30% of the mice survived 72 h after LPS induction with the lowest REE at around 22–24 h later (REE at 22 h: 2.26 ± 0.34 kcal/day p < 0.05 vs. baseline). Blood concentrations of TNF-α were highest at the 12 h timepoint (41.23 ± 24.39 pg/mL, p < 0.05 vs. baseline) and IL-6 was highest at 24 h after LPS induction (1476.5 ± 274.7 pg/mL, p < 0.05 vs. baseline). With V-Slope, we observed the AT at each timepoint (6 h:14 m/min,12 h: 9 m/min, 24 h:4 m/min,36 h:10 m/min, 48 h:16 m/min, 60 h:20 m/min, 72 h:22 m/min) and classified these into very low intensity exercise training, low intensity exercise training, or moderate intensity exercise training at each timepoint. Conclusion: We classified exercise intensities out to 72 h after sepsis recovery using a mouse model. These data may serve as a bridge to clinical studies to fill gaps in best practice for sepsis rehabilitation.
KW - Early mobilization
KW - Sepsis
KW - Translational study
UR - http://www.scopus.com/inward/record.url?scp=85103474253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103474253&partnerID=8YFLogxK
U2 - 10.1016/j.medidd.2020.100074
DO - 10.1016/j.medidd.2020.100074
M3 - Article
AN - SCOPUS:85103474253
SN - 2590-0986
VL - 9
JO - Medicine in Drug Discovery
JF - Medicine in Drug Discovery
M1 - 100074
ER -